Spain: Technical proposal to health authorities to combat therapeutic non-compliance

9 December 2016
spain-big

Half of Spanish patients suffering from chronic illnesses do not correctly follow the prescribed pharmacotherapeutic treatment, according to new research.

This data, which emerges from a survey of 1,400 patients commissioned by the pharma trade group Farmaindustria, reflects the real scale of the problem of the lack of adherence to treatments, which has consequences both for the health of the patient and for the quality and sustainability of the health system. To address this challenge, the Treatment Adherence Plan (responsible use of medicine), has been presented in Barcelona, a document which was prepared by scientific medical societies, pharmaceutical and nursing societies, patient representatives and professional experts, and promoted by Farmaindustria, is at the disposal of the sanitary authorities for its study and eventual application.

The Plan proposes a complete work strategy that arises from the vision of both healthcare professionals and patients. It is an unprecedented project, both integral and inclusive, transversal, ambitious and with the use of being applicable and continuous. In short, it is a proposal that civil society brings to public health administrations with the objective of improving the quality of health care and, above all, the health of patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical